@NanobiotechLab

Laboratory @ACBDresearch @MonashCCS @MonashUni led by Professor @cehagemeyer with a focus on antibody-based delivery of novel therapeutics and diagnostics

 Melbourne, Victoria
monash.edu/medicine/ccs/blood-disease/research/hagemeyer
Joined August 2017
  • Tweets433
  • Following1.2K
  • Followers907
35Media
As historic MDMA decision nears, even J.P. Morgan eyes psychedelic investments fiercebiotech.com/biotech/jp…

As historic MDMA decision nears, even J.P. Morgan eyes psychedelic investments

With the stage set for the first psychedelic-based therapy to nab FDA approval this year, even J.P. Morgan can't resist the allure of compelling data and wide-open markets. | With the stage set for...

fiercebiotech.com
1
1
170
Longboard’s shares triple as epilepsy med halves seizure rates in early-stage trial fiercebiotech.com/biotech/lo…

Longboard’s shares triple as epilepsy med halves seizure rates in early-stage trial

What do you get when you halve the number of seizures across a group of difficult epilepsy disorders in an early-stage trial? | What do you get when you halve the number of seizures across a group of...

fiercebiotech.com
1
234
Wishing everyone a wonderful festive season, fortunate to work and collaborate with such amazing people everyday, all the best for 2024.
7
240
Scalable human embryo model displays earliest stages of blood cell production fiercebiotech.com/research/s…

Scalable human embryo model displays earliest stages of blood cell production

Scientists have grown a scalable new embryo-like model that unshrouds some mysteries of early human development, including blood cell formation, or hematopoiesis—a first for the field.  | Scientists...

fiercebiotech.com
2
180
UPDATE: Roche muscles in on obesity market with $2.7B Carmot buyout, securing injectable and oral assets fiercebiotech.com/biotech/ro…

UPDATE: Roche muscles in on obesity market with $2.7B Carmot buyout, securing injectable and oral...

Roche is paying $2.7 billion upfront to | Roche is paying $2.7 billion upfront to enter the obesity market. The takeover will give Roche control of Carmot Therapeutics, a biotech with injectable dual...

fiercebiotech.com
133
AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field fiercepharma.com/pharma/abbv…

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal.  | The sizzling antibody-drug conjugate field is at the center of another major life sciences...

fiercepharma.com
119
NanoBiotechnology Laboratory retweeted
VBIC@VicBioImaging14 Nov 2023
Just over a week until the VBIC Annual Network Meeting! Don't miss out on this opportunity to hear about the latest innovations in imaging research, as well as industry and commercialisation insights! Secure your spot now- eventbrite.com.au/e/69150212…
3
1
6
732
NanoBiotechnology Laboratory retweeted
VBIC@VicBioImaging2 Nov 2023
We are only 3 weeks away from the VBIC Annual Network Meeting!! Be sure to seize this opportunity to join fellow researchers and industry partners in Victoria's imaging community. Register now to secure your spot: eventbrite.com.au/e/victoria…
4
2
9
1,113
ESMO: As peers enter radiopharmaceuticals, Novartis says welcome to the party fiercebiotech.com/biotech/es…

ESMO: As peers enter radiopharmaceuticals, Novartis says welcome to the party

MADRID—Novartis’ Jeff Legos, Ph.D., is watching peers like Eli Lilly move into radiopharmaceuticals. He knows what’s ahead for them. | MADRID—Novartis’ Jeff Legos, Ph.D., is watching peers like Eli...

fiercebiotech.com
1
125
Roche's BTK inhibitor may have reached 'holy grail' of brain penetration in phase 2 MS trial fiercebiotech.com/biotech/ro…

Roche's BTK inhibitor may have reached 'holy grail' of brain penetration in phase 2 MS trial

Roche has claimed the latest phase 2 readout for its multiple sclerosis (MS) drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing | Roche...

fiercebiotech.com
105
Incidental CAC missed in CT chest scans: study: thelimbic.com/cardiology/inc…

Incidental CAC missed in CT chest scans: study

Doctors often overlook incidental coronary artery calcification on non-cardiac CT scans, resulting in missed opportunities for statin therapy, an Australian study suggests. Researchers say their...

thelimbic.com
1
89
Novartis targets first-line use for radiotherapy Lutathera after trial win in neuroendocrine tumors fiercepharma.com/pharma/nova…

Novartis targets first-line use for radiotherapy Lutathera after trial win in neuroendocrine tumors

More than five years after an initial FDA approval, Novartis is touting positive trial results for its radiotherapy Lutathera as a first-line therapy against the rare cancer that killed Apple co-fo |...

fiercepharma.com
1
107
'Quantum therapeutic' triggers glioblastoma cells to self-destruct fiercebiotech.com/research/q…

'Quantum therapeutic' triggers glioblastoma cells to self-destruct

In a development fit for a Marvel movie, researchers from the U.K.'s University of Nottingham claim to have developed what they describe as the first “quantum therapeutic”—electrically-charged | In a...

fiercebiotech.com
55
Blackstone's $250M bet beats Xarelto in bleeding trial, making case for Anthos' ex-Novartis asset fiercebiotech.com/biotech/bl…

Blackstone's $250M bet beats Xarelto in bleeding trial, making case for Anthos' ex-Novartis asset

Blackstone Life Sciences’ $250 million bet on an ex-Novartis drug candidate has racked up another phase 2 win. | Blackstone Life Sciences’ $250 million bet on an ex-Novartis drug candidate has racked...

fiercebiotech.com
1
71
No more needles, an oral insulin medication could be on the horizon - Advanced Science News advancedsciencenews.com/no-m…

No more needles, an oral insulin medication could be on the horizon - Advanced Science News

A self-assembling helix formed from nateglinide, a complementary diabetes treatment, provides a protective coating that could open the door to an oral insulin medication.

advancedsciencenews.com
82
Eli Lilly hops aboard for Mariana Oncology's $175M series B, radiopharmaceuticals mission fiercebiotech.com/biotech/el…

Eli Lilly hops aboard for Mariana Oncology's $175M series B, radiopharmaceuticals mission

Investors have dived deep into their wallets for Mariana Oncology’s series B financing, with Eli Lilly coming aboard for the oversubscribed

fiercebiotech.com
60
Australian R&D spending drops as percentage of GDP shar.es/agn3nI
100
RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3 fiercebiotech.com/biotech/ra…

RayzeBio plans IPO to push radiotherapy 'pipeline-in-a-product' through phase 3

RayzeBio has already persuaded investors to hand over more than $400 million to pursue its targeted radiation approach to treating cancer. | RayzeBio has already persuaded investors to hand over more...

fiercebiotech.com
128
cendigitalmagazine.acs.org/2…?

Chemistry’s most powerful tools

Modern chemistry depends on analytical instruments. From the micro end of the spectrum—where researchers study reactions one molecule at a time—to the macro—where engineers run industrial reactors...

cendigitalmagazine.acs.org
57
Johns Hopkins makes major investment in the power, promise of data science and artificial intelligence bit.ly/3Ksp0Nz via @HubJHU
2
140
Load more